Sensex little changed as investors digest raid fallout

Image
Reuters
Last Updated : Sep 30 2016 | 12:42 PM IST

REUTERS - Indian shares were nearly unchanged in choppy trade on Friday, as investors turned cautious a day after India said it had conducted "surgical strikes" on suspected militants preparing to infiltrate from Pakistan-ruled Kashmir.

Sentiment also took a hit as global shares slumped on worries about the health of Deutsche Bank and as oil prices pulled back from near-one month highs on scepticism over OPEC's new plan to curb output.

MSCI's broadest index of Asia-Pacific shares outside Japan fell more than 1 percent, while Wall Street too lost about a percent on Thursday. [O/R] Indian officials said on Thursday elite troops crossed into Pakistan-ruled Kashmir and killed suspected militants preparing to infiltrate and carry out attacks on major cities, in a surprise raid that raised tensions between the nuclear-armed rivals.

Share markets in India and Pakistan fell after news of the raid on Thursday, with the Nifty falling as much 2.1 percent to its lowest since Aug. 29, while Pakistan's benchmark 100-share index dropped as much as 0.5 percent.

"The market will need some time to digest this problem...and it will wait and watch for a few days," said Vinod Nair, head of research with Geojit BNP Paribas Financial Securities.

The Nifty was down 0.02 percent at 8,589.95 by 0618 GMT on Friday, while the Sensex was 0.08 percent lower at 27,804.41.

Among the gainers, the Nifty IT index rose as much as 0.77 percent after two straight sessions of decline, led by Infosys Ltd and Wipro Ltd.

Auto stocks such as Eicher Motors Ltd and Mahindra and Mahindra Ltd gained as much as 2.53 percent and 1.76 percent, respectively.

Some financial stocks took a hit, with Housing Development Finance Corp among the top losers on the NSE index, falling as much as 1.40 percent.

Alkem Laboratories Ltd slumped as much as 8.80 pct to its lowest in two weeks, after the company on Thursday said it got 13 observations from the US FDA after an inspection at its Daman unit.

(Reporting by Darshana Sankararaman in Bengaluru; Editing by Biju Dwarakanath)

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 30 2016 | 12:26 PM IST

Next Story